CenTrak Named Global Healthcare RTLS Company of the Year by Frost & Sullivan
10 oct. 2024 09h05 HE
|
CenTrak, Inc.
CenTrak recognized as a global RTLS leader for its scalable location data and comprehensive suite of solutions on a unified platform
Amwell expands clinical programs portfolio to include Hello Heart cardiovascular health risk management solution
08 oct. 2024 07h05 HE
|
Amwell
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
Temperature Monitoring Devices Market to be Worth USD 5.3 billion by 2034, growing a CAGR 4.5% - Transparency Market Research, Inc.
01 oct. 2024 08h55 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The global temperature monitoring devices market (온도 모니터링 장치 시장) is estimated to surge at...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
30 sept. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
Key Highlights of Lighthouse Fusion
27 août 2024 09h00 HE
|
Lighthouse Autism Center
Lighthouse Autism Center expands its speech therapy program with more dually certified SLPs and BCBAs, offering better outcomes for children with autism.
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
07 août 2024 08h00 HE
|
Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
06 août 2024 08h00 HE
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
16 juil. 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...